Acadia Pharmaceuticals, Inc. (ACAD) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $20.59 -0.82%
Revenue Growth %: +19.3%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
SYRS, ZVOI, OMID, More
Revenue Growth %: +19.3%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
SYRS, ZVOI, OMID, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.04), $0.05 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $1.9 million.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kosmos Energy (KOS) Misses Q3 EPS by 3c
- Seagate Technology (STX) PT Lowered to $154 at UBS
- B.Riley Reiterates Buy Rating on Celsius Holdings (CELH) ahead of earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
